Viatris says that it remains on track to file a US investigational new drug application by the end of this year for the firm’s proposed biosimilar to the world-renowned Botox (onabotulinumtoxinA) cosmetic and therapeutic brand, in partnership with Revance Therapeutics, ahead of plans to initiate a landmark clinical study program in the first half of 2024.
“Our Botox biosimilar program is progressing well, from the development characterization and validation of drug substance and drug product perspective,” commented Viatris’ president Rajiv
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?